Class: Calcium channel blocking agent
- Tablets, extended-release 8.5 mg
- Tablets, extended-release 17 mg
- Tablets, extended-release 25.5 mg
- Tablets, extended-release 34 mg
Inhibits movement of calcium ions across cell membrane in systemic and coronary vascular smooth muscle and myocardium.
Nisoldipine is well absorbed. Absolute bioavailability is 5% and T max is 9.2 to 5.1 h. High-fat food results in significant increase in peak concentration (up to 245%) and a decrease in AUC by 25%.
Presystemic metabolism of nisoldipine in gut wall and liver by CYP-450 enzymes.
87% of the radiolabeled drug is recovered in urine and feces. Nisoldipine is eliminated 60% to 80% in urine (traces unchanged), 5 urinary metabolites and only 1 active. The t ½ is 13.7 to 4.3 h.
Special PopulationsRenal Function Impairment
Dosage adjustments are not needed in patients with mild to moderate renal function impairment.Elderly
Higher nisoldipine plasma concentrations (C max and AUC) have been found in elderly.Liver cirrhosis
Increased plasma concentrations. Use lower starting and maintenance doses.
Indications and Usage
Treatment of hypertension, alone or in combination with other antihypertensive agents.
Sensitivity to dihydropyridine calcium channel blockers.
Dosage and AdministrationAdults
PO Initiate therapy with 17 mg once daily, then increase by 8.5 mg/wk, or with longer intervals, to attain adequate BP control (max, 34 mg/day).Patients older than 65 yr of age, or patients with impaired liver function
Initiate therapy with 8.5 mg once daily.
- Have patient swallow tablets whole. Do not allow patient to crush, chew, or divide.
- Administer once daily 1 h before or 2 h after a meal. Do not administer with a high-fat meal. Avoid grapefruit products.
Store at 68° to 77°F. Protect from light and moisture.
Drug InteractionsCYP3A4 inducers (eg, carbamazepine, phenytoin)
Because nisoldipine is a substrate for CYP3A4, in general, avoid coadministration with CYP3A4 inducers. Nisoldipine plasma levels may be reduced, decreasing the efficacy.CYP3A4 inhibitors (eg, azole antifungal agents [eg, itraconazole, ketoconazole], cimetidine, grapefruit juice, quinidine)
Because nisoldipine is a substrate for CYP3A4, in general, avoid coadministration with CYP3A4 inhibitors. Nisoldipine plasma levels may be elevated, increasing the pharmacologic effect and adverse reactions.
Laboratory Test Interactions
None well documented.
Vasodilation (4%); palpitation (3%).
Headache (22%); dizziness (5%).
Systemic hypersensitivity including angioedema, chest tightness, hypotension, rash, shortness of breath, and tachycardia (postmarketing).
Peripheral edema (22%); chest pain (2%).
Monitor BP during initial administration and titration.
Category C .
Safety and efficacy not established.
Use with caution, usually starting at the low end of the dosage range because of the greater frequency of decreased hepatic, renal, or cardiac function, and concomitant diseases or other drug therapy.
Use drug with caution in patients with severe hepatic function impairment.
Contains FD&C Yellow No. 5. Use with caution in patients with aspirin sensitivity.
Use drug with caution in patients with CHF or compromised ventricular function.
Coronary artery disease
Sometimes, patients, particularly those with severe obstructive coronary artery disease, may have increased frequency, duration, or severity of angina or acute MI at start of therapy or when dose is increased.
- Instruct patient not to chew, crush, or divide extended-release tablets.
- Advise patient not to take with a high-fat meal and to avoid grapefruit products before and after dosing.
- Advise patient to take the medication once daily as directed even if they have no symptoms.
- Teach patient correct technique for monitoring BP and pulse daily.
- Advise patient that drug may cause dizziness and to use caution while driving or performing other tasks requiring mental alertness.
- Instruct patient to report the following symptoms to health care provider: dizziness; headache; increasing chest pain; palpitations; swelling of ankles, feet, or hands.
- Stress the need to comply with the other components of the hypertensive regimen, such as dietary changes, weight loss, and exercise.
- Instruct patient never to suddenly stop taking the medication.
Copyright © 2009 Wolters Kluwer Health.
More Nisoldipine resources
- Nisoldipine Prescribing Information (FDA)
- Nisoldipine Monograph (AHFS DI)
- nisoldipine Advanced Consumer (Micromedex) - Includes Dosage Information
- nisoldipine Concise Consumer Information (Cerner Multum)
- nisoldipine extended-release tablets MedFacts Consumer Leaflet (Wolters Kluwer)
- Sular Prescribing Information (FDA)